Last updated: March 2, 2026
What is MYDAYIS?
MYDAYIS (mixed salts of dextroamphetamine and amphetamine) is an extended-release central nervous system stimulant approved for the treatment of attention deficit hyperactivity disorder (ADHD) in individuals aged 13 and older. It delivers a controlled dose over approximately 12 hours, improving adherence and symptom management.
What are the key excipients in MYDAYIS?
MYDAYIS employs a multi-particulate extended-release matrix. The formulation includes:
- Dextroamphetamine and amphetamine salts: Active pharmaceutical ingredients (APIs).
- Povidone (polyvinylpyrrolidone): Binds API particles, facilitating uniform distribution within the matrix.
- Hydroxypropyl methylcellulose (HPMC): Forms the controlled-release matrix, controlling drug diffusion.
- Microcrystalline cellulose: Serves as an inactive filler and binder, providing structural integrity.
- Magnesium stearate: A lubricant aiding manufacturing processes.
- Titanium dioxide: Provides opacity to the coating system.
These excipients are selected for their stability, safety, and ability to modulate drug release.
How does excipient choice influence MYDAYIS's release profile?
The formulation's success hinges on excipients that control release kinetics:
- Hydroxypropyl methylcellulose (HPMC): A hydrophilic polymer forming a gel barrier upon contact with gastrointestinal fluids; prolongs drug release over 12 hours.
- Microcrystalline cellulose: Adds porosity, affecting drug diffusion and disintegration characteristics.
- Povidone: Ensures uniform drug distribution and aids in matrix formation.
Alterations to excipient ratios or properties directly impact pharmacokinetics, affecting onset, duration, and dose flexibility.
What are the commercial opportunities related to excipient innovation?
1. Development of Next-Generation Extended-Release Matrices
Innovating with excipients such as novel polymers or polymer blends can improve:
- Release consistency: Reducing variability due to pH or gastrointestinal transit differences.
- Dose personalization: Enabling more flexible dosing through modulated release profiles.
- Manufacturing efficiency: Lowering costs or simplifying processes.
Companies developing proprietary excipient blends or novel polymers could license or co-develop formulations for MYDAYIS or similar products.
2. Co-Formulation with Multiple APIs
Designing excipient systems to support combination therapies enhances treatment options. For example, combining stimulant and non-stimulant agents requires excipient matrices accommodating different solubilities and release needs.
3. Bioavailability Enhancement
Incorporating excipients like lipids or surfactants may improve drug absorption, especially for formulations seeking to optimize the onset or offset of action.
4. Patent Expansions Through Excipients
Patents protecting specific excipient compositions or manufacturing processes can extend exclusivity periods. This strategy can hinder generic competition and increase market share.
5. Focus on Abuse-Deterrent Formulations
Designing excipient systems that resist manipulation (e.g., crush resistance, abuse-deterrent coatings) can generate new market segments and meet regulatory scrutiny.
6. Supply Chain Stability and Cost Optimization
Partnerships with excipient manufacturers focusing on high-purity, sustainable, or low-cost raw materials can secure supply and reduce production expenses.
What are regulatory considerations for excipient strategies?
Regulatory agencies such as the FDA require comprehensive safety data for excipients, especially when used in novel or modified formulations. Excipients must meet Pharmacopoeia standards and demonstrate compatibility with APIs, stability, and intended release profiles.
Any formulation change involving excipients constitutes a supplement or new drug application, necessitating bioavailability and bioequivalence studies, depending on the scope.
Market Trends and Competitive Landscape
- The global ADHD treatment market valued at USD 14.4 billion in 2021 is expected to grow annually by 6.2%.
- Extended-release formulations like MYDAYIS hold approximately 60% of this market segment.
- Competitors such as Adderall XR and Vyvanse utilize comparable excipient strategies but differ in matrix materials and release mechanisms.
Summary of Key Data Points
| Aspect |
Details |
| Active ingredients |
Dextroamphetamine and amphetamine salts |
| Major excipients |
Povidone, HPMC, microcrystalline cellulose, magnesium stearate, titanium dioxide |
| Release profile |
12-hour extended release |
| Manufacturing considerations |
Matrix formation, matrix coating, particle size control |
| Patent status |
Multiple patents on formulation and process |
| Regulatory pathway |
NDA submission, stability testing, bioequivalence studies |
Key Takeaways
- MYDAYIS’s excipient strategy centers on employing HPMC and other matrix-forming agents to control release over 12 hours.
- Innovations in excipient chemistry present opportunities to improve release profiles, enable combination therapies, and develop abuse-deterrent formulations.
- Patent extension and market differentiation hinge on novel excipient blends and processing techniques.
- Regulatory considerations stress safety, compatibility, and demonstration of equivalence for formulation changes.
- Market growth driven by rising ADHD prevalence and demand for long-acting formulations sustains opportunities for excipient and formulation innovation.
FAQs
Q1: Which excipients are critical for MYDAYIS’s extended-release profile?
Hydroxypropyl methylcellulose (HPMC) forms the gel matrix controlling drug release; microcrystalline cellulose influences disintegration and porosity.
Q2: Can new excipients improve MYDAYIS's pharmacokinetics?
Yes, novel polymers or lipid-based excipients can modify release rates, onset, and bioavailability.
Q3: What regulatory hurdles exist for excipient modifications?
Any change requires bioequivalence data, stability testing, and regulatory approval, as per the FDA and EMA requirements.
Q4: How can excipient innovation create competitive advantage?
By offering improved pharmacokinetic profiles, abuse resistance, and patentable formulations, excipient innovations can extend lifecycle and market share.
Q5: What market segments besides ADHD treatment could benefit from similar excipient strategies?
Other neuropsychiatric, pain, and chronic disease formulations utilizing controlled-release matrices can adopt similar excipient approaches.
References
[1] U.S. Food and Drug Administration (FDA). (2020). Extended-release and controlled-release drug products. Retrieved from https://www.fda.gov/
[2] Statista. (2022). ADHD treatment market size and forecasts. Retrieved from https://www.statista.com/
